ALK and non-small cell lung carcinoma: This has resulted in significant progress in the treatment of oncogene driven lung cancers such as EGFR, BRAF, MET, KRAS and HER2 mutant and ALK, ROS1, RET, NTRK1-3 translocation positive NSCLC with tyrosine kinase inhibitors (TKIs) targeting these oncogenes [2].